Successful Targeting of Alzheimer's Disease 2011
June 7 - 8, 2011
Filadelfia PA , Stati Uniti
HUMAN GENETICS
What Can Recent Genetic Data Teach Us About Novel Therapeutics for Alzheimer’s Disease?
Rudolph Tanzi, Ph.D., Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
A TOMM-40 Variable Length Polyt Repeat Polymorphism, Inherited through Evolution, Determines the Age of Onset Distribution of Late-Onset Alzheimer’s Disease
Allen D. Roses, M.D., Director, Deane Drug Discovery Institute, Duke University
TARGETS
Studies Probing the Mechanism of Action of Allosteric γ-Secretase Inhibitors and Modulators
Douglas S. Johnson, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Pfizer, Inc.
Potential for the Treatment and Prevention of Alzheimer’s Disease with Liver X Receptor Agonist
Celina Zerbinatti, Ph.D., Team Lead, Cognitive Disorders, Department of Neurosymptomatic Disorders, Merck & Co., Inc.
Synaptic Zinc as a Pharmacological Target in Alzheimer’s Disease
Ashley I. Bush, M.D., Ph.D., Director, Oxidation Biology Laboratory, Mental Health Research Institute, Victoria, Australia; Professor of Pathology, University of Melbourne; Lecturer in Psychiatry, Harvard Medical School, Massachusetts General Hospital; Adjunct Professor of Neuroscience, Cornell University Medical Center, New York
ANIMAL MODELS
A Canine Model for Evaluating Gamma Secretase Modulators and Inhibitors
Herman Borghys, Ph.D., Neuroscience, Janssen Pharmaceutica, a division of Johnson & Johnson Pharmaceutical Research and Development
IMAGING & BIOMARKERS
The Impact of the ADNI on Drug Discovery & Development
William Potter, Ph.D., former Vice President, Translational Neuroscience, Merck Research Laboratories
Talk Title to be Announced
Leslie Shaw, Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Expert
What Can Recent Genetic Data Teach Us About Novel Therapeutics for Alzheimer’s Disease?
Rudolph Tanzi, Ph.D., Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
A TOMM-40 Variable Length Polyt Repeat Polymorphism, Inherited through Evolution, Determines the Age of Onset Distribution of Late-Onset Alzheimer’s Disease
Allen D. Roses, M.D., Director, Deane Drug Discovery Institute, Duke University
TARGETS
Studies Probing the Mechanism of Action of Allosteric γ-Secretase Inhibitors and Modulators
Douglas S. Johnson, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Pfizer, Inc.
Potential for the Treatment and Prevention of Alzheimer’s Disease with Liver X Receptor Agonist
Celina Zerbinatti, Ph.D., Team Lead, Cognitive Disorders, Department of Neurosymptomatic Disorders, Merck & Co., Inc.
Synaptic Zinc as a Pharmacological Target in Alzheimer’s Disease
Ashley I. Bush, M.D., Ph.D., Director, Oxidation Biology Laboratory, Mental Health Research Institute, Victoria, Australia; Professor of Pathology, University of Melbourne; Lecturer in Psychiatry, Harvard Medical School, Massachusetts General Hospital; Adjunct Professor of Neuroscience, Cornell University Medical Center, New York
ANIMAL MODELS
A Canine Model for Evaluating Gamma Secretase Modulators and Inhibitors
Herman Borghys, Ph.D., Neuroscience, Janssen Pharmaceutica, a division of Johnson & Johnson Pharmaceutical Research and Development
IMAGING & BIOMARKERS
The Impact of the ADNI on Drug Discovery & Development
William Potter, Ph.D., former Vice President, Translational Neuroscience, Merck Research Laboratories
Talk Title to be Announced
Leslie Shaw, Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Expert
Eventi correlati
Successful Targeting of Alzheimer's Disease June 16 - 17, 2013
Successful Targeting of Alzheimer's Disease June 5 - 6, 2012
Successful Targeting of Alzheimer's Disease June 7 - 8, 2011